Literature DB >> 30984972

Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.

Ruitao Lin1, Ying Yuan1.   

Abstract

Two useful strategies to speed up drug development are to increase the patient accrual rate and use novel adaptive designs. Unfortunately, these two strategies often conflict when the evaluation of the outcome cannot keep pace with the patient accrual rate and thus the interim data cannot be observed in time to make adaptive decisions. A similar logistic difficulty arises when the outcome is late-onset. Based on a novel formulation and approximation of the likelihood of the observed data, we propose a general methodology for model-assisted designs to handle toxicity data that are pending due to fast accrual or late-onset toxicity and facilitate seamless decision making in phase I dose-finding trials. The proposed time-to-event model-assisted designs consider each dose separately and the dose-escalation/de-escalation rules can be tabulated before the trial begins, which greatly simplifies trial conduct in practice compared to that under existing methods. We show that the proposed designs have desirable finite and large-sample properties and yield performance that is comparable to that of more complicated model-based designs. We provide user-friendly software for implementing the designs.
© The Author 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Adaptive design; Dose finding; Late-onset toxicity; Maximum tolerated dose; Model-assisted designs

Mesh:

Year:  2020        PMID: 30984972      PMCID: PMC8559898          DOI: 10.1093/biostatistics/kxz007

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  21 in total

1.  Dose-response curve estimation: a semiparametric mixture approach.

Authors:  Ying Yuan; Guosheng Yin
Journal:  Biometrics       Date:  2011-05-31       Impact factor: 2.571

2.  Bayesian optimal interval design for dose finding in drug-combination trials.

Authors:  Ruitao Lin; Guosheng Yin
Journal:  Stat Methods Med Res       Date:  2015-07-15       Impact factor: 3.021

3.  STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.

Authors:  Ruitao Lin; Guosheng Yin
Journal:  Stat Med       Date:  2017-08-07       Impact factor: 2.373

4.  Robust EM Continual Reassessment Method in Oncology Dose Finding.

Authors:  Ying Yuan; Guosheng Yin
Journal:  J Am Stat Assoc       Date:  2011-09-01       Impact factor: 5.033

5.  Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Authors:  Sophie Postel-Vinay; Carlos Gomez-Roca; L Rhoda Molife; Bhavesh Anghan; Antonin Levy; Ian Judson; Johann De Bono; Jean-Charles Soria; Stan Kaye; Xavier Paoletti
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

6.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

7.  Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.

Authors:  Heng Zhou; Ying Yuan; Lei Nie
Journal:  Clin Cancer Res       Date:  2018-04-16       Impact factor: 12.531

8.  Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.

Authors:  Fangrong Yan; Sumithra J Mandrekar; Ying Yuan
Journal:  Clin Cancer Res       Date:  2017-05-25       Impact factor: 12.531

9.  Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.

Authors:  Ying Yuan; Ruitao Lin; Daniel Li; Lei Nie; Katherine E Warren
Journal:  Clin Cancer Res       Date:  2018-05-16       Impact factor: 12.531

10.  Shortening the timeline of pediatric phase I trials: the rolling six design.

Authors:  Jeffrey M Skolnik; Jeffrey S Barrett; Bhuvana Jayaraman; Dimple Patel; Peter C Adamson
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

View more
  8 in total

1.  Adaptive Phase 1 Design in Radiation Therapy Trials.

Authors:  Nolan A Wages; Thomas M Braun; Daniel P Normolle; Matthew J Schipper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2022-07-01       Impact factor: 8.013

2.  TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.

Authors:  Yanhong Zhou; Ruitao Lin; J Jack Lee; Daniel Li; Li Wang; Ruobing Li; Ying Yuan
Journal:  Stat Med       Date:  2022-01-31       Impact factor: 2.497

3.  Response adaptive designs for Phase II trials with binary endpoint based on context-dependent information measures.

Authors:  Ksenia Kasianova; Mark Kelbert; Pavel Mozgunov
Journal:  Comput Stat Data Anal       Date:  2021-06       Impact factor: 1.681

4.  A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.

Authors:  Jian Wang; Junsheng Ma; Chunyan Cai; Naval Daver; Jing Ning
Journal:  Stat Med       Date:  2021-06-07       Impact factor: 2.497

5.  An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.

Authors:  Rongji Mu; Zongliang Hu; Guoying Xu; Haitao Pan
Journal:  BMC Med Res Methodol       Date:  2021-12-13       Impact factor: 4.615

6.  Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.

Authors:  Masahiro Kojima
Journal:  BMC Med Res Methodol       Date:  2022-04-06       Impact factor: 4.615

Review 7.  Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials.

Authors:  Lai Wei; Xueliang Pan; Soledad Fernandez
Journal:  Future Drug Discov       Date:  2019-10-11

8.  SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials.

Authors:  Yifei Zhang; Beibei Guo; Sha Cao; Chi Zhang; Yong Zang
Journal:  Pharm Stat       Date:  2022-03-24       Impact factor: 1.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.